Zobrazeno 1 - 10
of 77
pro vyhledávání: '"Kuniko, Matsuda"'
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-12 (2024)
Abstract Small cell lung cancer (SCLC) is well known as a highly malignant neuroendocrine tumor. Immunotherapy combined with chemotherapy has become a standard treatment for extensive SCLC. However, since most patients quickly develop resistance and
Externí odkaz:
https://doaj.org/article/97fd13128be2457faeead90f866ebbb3
Autor:
Yasuhiro Kato, Masaru Matsumoto, Natsuki Takano, Mariko Hirao, Kuniko Matsuda, Takehiro Tozuka, Naomi Onda, Shinji Nakamichi, Susumu Takeuchi, Akihiko Miyanaga, Rintaro Noro, Akihiko Gemma, Masahiro Seike
Publikováno v:
Cancer Medicine, Vol 13, Iss 12, Pp n/a-n/a (2024)
Abstract Introduction A neurotrophic tropomyosin receptor kinase (NTRK)‐tyrosine kinase inhibitor (TKI) has shown dramatic efficacy against malignant tumors harboring an NTRK fusion gene. However, almost all tumors eventually acquire resistance to
Externí odkaz:
https://doaj.org/article/7e17ba81b3294778a9a44409ba4acb39
Autor:
Takehiro Tozuka, MD, Rintaro Noro, MD, PhD, Keisuke Yoshida, PhD, Satoshi Takahashi, MD, PhD, Mariko Hirao, MD, Kuniko Matsuda, MD, Yasuhiro Kato, MD, Shinji Nakamichi, MD, PhD, Susumu Takeuchi, MD, PhD, Masaru Matsumoto, MD, PhD, Akihiko Miyanaga, MD, PhD, Shinobu Kunugi, MD, PhD, Kazufumi Honda, DDS, PhD, Jun Adachi, PhD, Masahiro Seike, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 5, Iss 4, Pp 100668- (2024)
Introduction: Osimertinib is a standard treatment for patients with EGFR-mutant NSCLC. Although some osimertinib resistance mechanisms have been identified, nearly 50% of the mechanisms remain to be elucidated. This study was aimed at identifying non
Externí odkaz:
https://doaj.org/article/28ffabd2f77f47d7942680f03c8b460c
Autor:
Miwako Omori, Rintaro Noro, Masahiro Seike, Kuniko Matsuda, Mariko Hirao, Aya Fukuizumi, Natsuki Takano, Akihiko Miyanaga, Akihiko Gemma
Publikováno v:
Thoracic Cancer, Vol 13, Iss 15, Pp 2142-2151 (2022)
Abstract Background Small cell lung cancer (SCLC) is a highly aggressive disease with a poor prognosis. Although most patients initially respond to topoisomerase inhibitors, resistance rapidly emerges. The aim, therefore, is to overcome resistance to
Externí odkaz:
https://doaj.org/article/67ccadb8f9304be1b1ff18d17e4b8dec
Autor:
Masamitsu Shimizu, Akihiko Miyanaga, Masahiro Seike, Kuniko Matsuda, Masaru Matsumoto, Rintaro Noro, Kazue Fujita, Yoko Mano, Nobuhiko Furuya, Kaoru Kubota, Akihiko Gemma
Publikováno v:
Thoracic Cancer, Vol 13, Iss 13, Pp 1940-1947 (2022)
Abstract Background Research has shown that some microbiomes are linked to cancer. Hence, we hypothesize that alterations in the respiratory microbiome might be associated with lung cancer. Methods Through droplet digital polymerase chain reaction an
Externí odkaz:
https://doaj.org/article/0ab633eded5342b0b12ea89922f120f8
Autor:
Kakeru Hisakane, Masahiro Seike, Teppei Sugano, Akiko Yoshikawa, Kuniko Matsuda, Natsuki Takano, Satoshi Takahashi, Rintaro Noro, Akihiko Gemma
Publikováno v:
Thoracic Cancer, Vol 12, Iss 11, Pp 1690-1698 (2021)
Abstract Background Osimertinib is a third‐generation epidermal growth factor receptor‐tyrosine kinase inhibitor (EGFR‐TKI) approved for the treatment of patients with EGFR‐mutant non‐small cell lung cancer (NSCLC). However, the mechanisms
Externí odkaz:
https://doaj.org/article/c14b21fa953a409e997e157793121450
Autor:
Aya Fukuizumi, MD, Rintaro Noro, MD, PhD, Masahiro Seike, MD, PhD, Akihiko Miyanaga, MD, PhD, Yuji Minegishi, MD, PhD, Miwako Omori, MD, Mamiko Hirao, Kuniko Matsuda, Shinobu Kunugi, MD, PhD, Kazutaka Nishiwaki, Masahiro Morimoto, Haruka Motohashi, Hayato Ohwada, PhD, Jitsuo Usuda, MD, PhD, Akihiko Gemma, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 2, Iss 11, Pp 100232- (2021)
Introduction: To investigate the genomic profiles of patients with lung cancer with idiopathic pulmonary fibrosis (IPF-LC), mechanism of carcinogenesis, and potential therapeutic targets. Methods: We analyzed 29 matched, surgically resected, cancerou
Externí odkaz:
https://doaj.org/article/790906db2fa7483283e2b97f1365bd03
Autor:
Koichiro Kamio, Arata Azuma, Kuniko Matsuda, Jiro Usuki, Minoru Inomata, Akemi Morinaga, Takeru Kashiwada, Nobuhiko Nishijima, Shioto Itakura, Nariaki Kokuho, Kenichiro Atsumi, Hiroki Hayashi, Tomoyoshi Yamaguchi, Kazue Fujita, Yoshinobu Saito, Shinji Abe, Kaoru Kubota, Akihiko Gemma
Publikováno v:
Respiratory Research, Vol 19, Iss 1, Pp 1-14 (2018)
Abstract Background Idiopathic pulmonary fibrosis (IPF) is a progressive disease with high mortality, and the pathogenesis of the disease is still incompletely understood. Although lymphocytes, especially CD4+CD25+FoxP3+ regulatory T cells (Tregs), h
Externí odkaz:
https://doaj.org/article/310fc39757ee423ab077a014bf1700ad
Autor:
Miwako Omori, Rintaro Noro, Masahiro Seike, Kuniko Matsuda, Mariko Hirao, Aya Fukuizumi, Natsuki Takano, Akihiko Miyanaga, Akihiko Gemma
Publikováno v:
Thoracic Cancer. 13:2142-2151
Small cell lung cancer (SCLC) is a highly aggressive disease with a poor prognosis. Although most patients initially respond to topoisomerase inhibitors, resistance rapidly emerges. The aim, therefore, is to overcome resistance to topoisomerase I (ir
Autor:
Akihiko Gemma, Kaoru Kubota, Yuji Minegishi, Rintaro Noro, Hideaki Mizutani, Akihiko Miyanaga, Kuniko Matsuda, Tetsuya Okano, Masahiro Seike, Kazuhiro Kitamura
Epithelial–mesenchymal transition (EMT) has recently been recognized as a key element of cell invasion, migration, metastasis, and drug resistance in several types of cancer, including non–small cell lung cancer (NSCLC). Our aim was to clarify mi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a6e3a0a5bb67a8d35d1fa84f51324160
https://doi.org/10.1158/1535-7163.c.6536274
https://doi.org/10.1158/1535-7163.c.6536274